Experimental cell therapy takes on deadliest brain tumors
NCT ID NCT07384390
First seen Feb 03, 2026 · Last updated Apr 28, 2026 · Updated 12 times
Summary
This early-phase study tests a new cell therapy called TH-CART-027 in 21 adults with recurrent or progressive grade 4 glioma, a fast-growing brain cancer. The treatment uses specially engineered immune cells to attack the tumor. The main goals are to check safety and see if the therapy can shrink tumors or extend survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for R/R GRADE 4 GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.